Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

162.99 +0.14 (+0.09%)
Official Closing Price Updated: 7:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now
These stocks could deliver big over the long term. 
Via The Motley Fool
This Magnificent Dividend Stock Is as Healthy as It Gets
Johnson & Johnson's latest financial checkup shows it's still in excellent health. 
Via The Motley Fool
Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say
Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated 2024 guidance reflects performance improvement but includes costs tied to... 
Via Benzinga
Johnson & Johnson Stock: Setting the Stage for 2025 Highs
Healthcare giant and Dividend Aristocrat Johnson & Johnson is on track to hit new highs in 2025 and may sustain its rally well into 2026. 
Via MarketBeat
Exposures COVID-19
Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?
Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024. 
Via The Motley Fool
Johnson & Johnson’s Medtech Segment Shines With Impressive Q3 Growth
Johnson & Johnson's third-quarter performance exceeded expectations, with adjusted EPS of $2.42 against an expected $2.19. 
Via Talk Markets
Why NYSE:JNJ is a Top Pick for Dividend Investors.
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics. 
Via Chartmill
This Is What Whales Are Betting On Johnson & Johnson
Via Benzinga
Are JNJ’s Mergers And Acquisitions Weighing Down Company’s Performance?
In the last two years, JNJ has invested over $30 billion in acquisitions. 
Via Talk Markets
Cancer Drugs Propel J&J Beyond Wall Street Estimates
On Tuesday, Johnson & Johnson (NYSE: JNJ) posted better-than-expected third quarter sales and adjusted profit. Fueled by strong results, Johnson & Johnson raised its full year profit and sales... 
Via Benzinga
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
JNJ earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results
Via Benzinga
Chipmaker Stocks Sink On ASML Earnings Leak, Oil Eyes Worst 1-Day Drop This Year, Small Caps Rally: What's Driving Markets Tuesday?
A wave of market-relevant news fueled an active trading session on Wall Street Tuesday, with large-cap indices falling due to sharp declines in tech and energy stocks, while small-caps outperformed,... 
Via Benzinga
Google Goes Nuclear For AI Power, Israeli Restraint Impacts Stocks, Gold, And Oil
To gain an edge, this is what you need to know today. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Johnson & Johnson's Q3 Earnings: Revenue And EPS Beat On Strong Cancer Drug Sales, Revises Annual Outlook To Reflect V-Wave Acquisition
Johnson & Johnson reported third-quarter earnings with adjusted EPS of $2.42, surpassing expectations. Sales rose 5.2% to $22.47B. J&J updated its 2024 adjusted EPS guidance, lowering it slightly to... 
Via Benzinga
Johnson & Johnson Earnings Top; Dow Giant Works Toward Buy Point
J&J stock edged higher early Tuesday. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Wall Street On Edge As Nasdaq Nears Record High, Oil Prices Plummet: Strategist Says There's Opportunity If Resilience Continues
Wall Street mood has become circumspect as traders gear up to receive a slew of earnings reports this week amid the market’s record run. The Nasdaq Composite has been a laggard among the major averages... 
Via Benzinga
Topics Stocks
Exposures US Equities
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Reports Q3 2024 Results
From Johnson & Johnson
Via Business Wire
Jim Cramer Says Earnings Season Will Fuel Market's Record Run, But Warns Of This 'Horrendous' Headwind That Could Apply Brakes To Rally
The stock market has been on a two-year strong run and the extended rally has begun to stir valuation concerns. 
Via Benzinga
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana. 
Via Talk Markets
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Via Benzinga
More Patients On Eli Lilly's Mirikizumab Achieved Histologic Response At One Year Compared To Johnson & Johnson's Drug
On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of mirikizumab compared with a placebo and active control (Johnson & Johnson’s... 
Via Benzinga
Johnson & Johnson Preps For Q3 Earnings As MedTech Expands, But Stock Sends Mixed Signals
JNJ's 3Q earnings expected to be $2.21 EPS and $22.16B revenue. Recent acquisitions and drug trials impacting stock's stagnant performance. 
Via Benzinga
Best Pharma Stocks for Long-Term Investors: Growth and Dividends
Big pharmaceutical firms may lack the potential for rally driven by a breakout drug like small biotechs, but stability and steady growth remain attractive. 
Via MarketBeat
Columbus Day: Is Stock Market Open Today?
Investors should brace for a busy week with earnings reports from major companies. 
Via Benzinga
Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
Eli Lilly is the most valuable pharmaceutical company in the world. I believe the company has what it takes to stay there. 
Via MarketBeat
All It Takes Is $1,000 Invested in Each of These 3 Dividend Kings to Help Generate Over $100 in Passive Income Per Year
Target, PepsiCo, and Kenvue have high yields and inexpensive valuations. 
Via The Motley Fool
Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12
Johnson & Johnson is a leader in the pharmaceutical, medical device, and consumer products industries. Here are some highlights from a quantitative analysis of the company's stock. 
Via Talk Markets
Stocks Extend Weekly Win Streaks To 5
Wall Street enjoyed healthy gains to close out both the day and week. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.